109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
核医学在预测肝细胞癌免疫治疗和靶向治疗反应中的作用：综述性评论
Received 3 June 2025
Accepted for publication 22 October 2025
Published 31 October 2025 Volume 2025:12 Pages 2445—2457
DOI https://doi.org/10.2147/JHC.S544565
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Mohamed Shaker
Haibin Tu,1 Dingluan Lin,2 Cailong Chen2
1Department of Ultrasound, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, People’s Republic of China; 2Department of PET, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, People’s Republic of China
Correspondence: Cailong Chen, Email 116235906@qq.com
Objective: Targeted and immunotherapy offer new treatment options for patients with advanced hepatocellular carcinoma (HCC); however, the proportion of patients who benefit from these therapies remains limited. Moreover, these treatments can involve complications and add financial burdens to patients, underscoring the need to identify those who are likely to benefit. As an advanced molecular imaging technique, nuclear medicine has the potential to predict treatment efficacy in targeted and immunotherapy, though its predictive accuracy remains uncertain. This narrative review aims to summarize existing research on nuclear medicine applications in this area, providing clinicians with new perspectives.
Materials and Methods: We conducted a literature review across multiple medical databases, including PubMed, Embase, Cochrane Library, Web of Science, and Scopus. Relevant studies were identified, organized, and summarized to present findings in the field.
Results: The findings indicate that metrics such as maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) correlate with the efficacy of targeted and immunotherapy. Additionally, emerging nuclear medicine techniques have shown promise in predicting PD-L1 expression.
Conclusion: Nuclear medicine holds potential for identifying patients who are likely to benefit from targeted and immunotherapy. However, further refinements are necessary to optimize its predictive capabilities.
Keywords: nuclear medicine, hepatocellular carcinoma, immunotherapy, targeted therapy, FDG PET/CT
1Department of Ultrasound, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, People’s Republic of China; 2Department of PET, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, People’s Republic of China
Correspondence: Cailong Chen, Email 116235906@qq.com
Objective: Targeted and immunotherapy offer new treatment options for patients with advanced hepatocellular carcinoma (HCC); however, the proportion of patients who benefit from these therapies remains limited. Moreover, these treatments can involve complications and add financial burdens to patients, underscoring the need to identify those who are likely to benefit. As an advanced molecular imaging technique, nuclear medicine has the potential to predict treatment efficacy in targeted and immunotherapy, though its predictive accuracy remains uncertain. This narrative review aims to summarize existing research on nuclear medicine applications in this area, providing clinicians with new perspectives.
Materials and Methods: We conducted a literature review across multiple medical databases, including PubMed, Embase, Cochrane Library, Web of Science, and Scopus. Relevant studies were identified, organized, and summarized to present findings in the field.
Results: The findings indicate that metrics such as maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) correlate with the efficacy of targeted and immunotherapy. Additionally, emerging nuclear medicine techniques have shown promise in predicting PD-L1 expression.
Conclusion: Nuclear medicine holds potential for identifying patients who are likely to benefit from targeted and immunotherapy. However, further refinements are necessary to optimize its predictive capabilities.
Keywords: nuclear medicine, hepatocellular carcinoma, immunotherapy, targeted therapy, FDG PET/CT